Previous post Next post

Korean firm bids CHF1.5bn for Swiss pharma supplier Polypeptide

The South Korean contract biopharmaceutical manufacturer Samsung Biologics intends to acquire the Swiss active pharmaceutical ingredient manufacturer Polypeptide. The company is offering CHF44.31 per share in cash, valuing Polypeptide at around CHF1.5 billion. Polypeptide’s board of directors supports the offer, both companies announced on Monday. The major shareholder, Draupnir Holding, which holds just under 56% of the shares, also intends to sell its stake. The offer is around 40% above the share price prior to the announcement of the takeover plans in April. Conditions for the deal include regulatory approval and the acceptance of at least two-thirds of the shares. Polypeptide manufactures so-called peptides. These are short protein building blocks used as active ingredients or components in modern medicines, for example to treat metabolic or hormonal disorders. Around 1,500 employees Founded in 1996, the active ingredient manufacturer traces its origins back to peptide ... Full story here Are you the author?
About Swissinfo
Swissinfo
SWI swissinfo.ch – the international service of the Swiss Broadcasting Corporation (SBC). Since 1999, swissinfo.ch has fulfilled the federal government’s mandate to distribute information about Switzerland internationally, supplementing the online offerings of the radio and television stations of the SBC. Today, the international service is directed above all at an international audience interested in Switzerland, as well as at Swiss citizens living abroad.
Previous post See more for 3.) Swissinfo Business and Economy Next post
Tags: ,,

Permanent link to this article: https://snbchf.com/2026/07/korean-firm-chf1-5bn-swiss-pharma-supplier-polypeptide/

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

This site uses Akismet to reduce spam. Learn how your comment data is processed.